Annual Secretarial Compliance Report for the year ended 31st March, 2025
Awaiting price reaction for this filing.
Piramal Pharma Limited has submitted its Annual Secretarial Compliance Report for FY 2024-25, prepared by NL Bhatia & Associates, Practicing Company Secretaries, as required under Regulation 24A of SEBI LODR Regulations. The report confirms full compliance across all 13 areas checked, including Secretarial Standards, SEBI policy adoption and updates, website disclosures, director eligibility, subsidiary identification, document preservation, board performance evaluation, related party transactions, event/information disclosures, and insider trading norms. No deviations, penalties, or SEBI/stock exchange actions were reported against the company, its promoters, directors, or subsidiaries during the year. The statutory auditor did not resign during the period, and no additional non-compliances were flagged. This is a routine annual regulatory filing with a clean compliance record.
No impact on shareholders — this confirms a clean compliance track record for FY2024-25, with no regulatory penalties or action. This is a routine procedural disclosure with no material information for stock price movement.